Fresenius Kabi sells cancer compounding biz to NewCo Pharma
The deal saw Mannheim-based NewCo Pharma GmbH take control of CRL, which specialises in the manufacture of patient specific preparations of injectable cancer treatments, including antibodies and cytostatics.
CFL has compounding centers in Aschaffenberg and Munich. It also has compounding pharmacies in Bonn (Compounding Rheinische), Mannheim (Fortuna Herstellung) Osnabruck, (Onco Service) and Stuttgart (cas central compounding baden-wuttemberg).
Fresnius spokesman Matthais Link confirmed the divestiture, telling in-Pharmatechnologist.com “We announced the sale of the German oncology compounding business being closed yesterday evening.”
He added that: “The deal includes all five compounding centres of CFL, the centre in Aschaffenburg [where the organisation is based] among them.”
Divestiture
Fresenius Kabi, CFL’s parent division, acquired cas central compounding baden-wuttemberg and Fortuna Herstellung in 2010 for €31m.
A year later it spent another €11m on compounding capacity in Germany.
The firm did not say what prompted it to divest CFL, which it said generated revenue of €77m ($87m) last year.
Link stressed that Fresnius will continue to operate in the compounding sector which – in Germany – will be focused on the production of intravenous nutrition products “because the company sees more attractive growth opportunities in this area. So we bundle our resources there.”
Mannheim-based NewCo Pharma was founded on January 1 by pharmacist Michael Schill and also focuses on IV oncology drug compounding.
